$29.17
18.63% yesterday
Nasdaq, Dec 24, 10:42 pm CET
ISIN
US00847X1046
Symbol
AGIO

Agios Pharmaceuticals, Inc. Stock price

$29.17
+2.68 10.12% 1M
-4.25 12.72% 6M
-3.69 11.23% YTD
-5.02 14.68% 1Y
+2.14 7.92% 3Y
-15.98 35.39% 5Y
-36.85 55.82% 10Y
-2.11 6.75% 20Y
Nasdaq, Closing price Wed, Dec 24 2025
+4.58 18.63%
ISIN
US00847X1046
Symbol
AGIO
Industry

Key metrics

Basic
Market capitalization
$1.7b
Enterprise Value
$748.2m
Net debt
positive
Cash
$952.9m
Shares outstanding
58.3m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
38.0 | 36.2
EV/Sales
16.7 | 15.9
EV/FCF
negative
P/B
1.3
Financial Health
Equity Ratio
92.7%
Return on Equity
43.7%
ROCE
-36.3%
ROIC
-112.6%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$44.8m | $47.0m
EBITDA
$-470.3m | $-481.8m
EBIT
$-475.6m | $-488.3m
Net Income
$-401.3m | $-419.6m
Free Cash Flow
$-414.1m
Growth (TTM | estimate)
Revenue
36.3% | 28.7%
EBITDA
-17.2% | -14.7%
EBIT
-16.9% | -14.7%
Net Income
-159.5% | -162.3%
Free Cash Flow
-25.5%
Margin (TTM | estimate)
Gross
87.2%
EBITDA
-1,050.0% | -1,025.2%
EBIT
-1,061.8%
Net
-895.9% | -893.0%
Free Cash Flow
-924.5%
More
EPS
$-6.9
FCF per Share
$-7.1
Short interest
9.4%
Employees
487
Rev per Employee
$70.0k
Show more

Is Agios Pharmaceuticals, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,079 stocks worldwide.

Agios Pharmaceuticals, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

16 Analysts have issued a Agios Pharmaceuticals, Inc. forecast:

12x Buy
75%
4x Hold
25%

Analyst Opinions

16 Analysts have issued a Agios Pharmaceuticals, Inc. forecast:

Buy
75%
Hold
25%

Financial data from Agios Pharmaceuticals, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
45 45
36% 36%
100%
- Direct Costs 5.73 5.73
64% 64%
13%
39 39
33% 33%
87%
- Selling and Administrative Expenses 180 180
28% 28%
403%
- Research and Development Expense 334 334
13% 13%
746%
-470 -470
17% 17%
-1,050%
- Depreciation and Amortization 5.28 5.28
8% 8%
12%
EBIT (Operating Income) EBIT -476 -476
17% 17%
-1,062%
Net Profit -401 -401
160% 160%
-896%

In millions USD.

Don't miss a Thing! We will send you all news about Agios Pharmaceuticals, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Agios Pharmaceuticals, Inc. Stock News

Neutral
Seeking Alpha
about 23 hours ago
Agios Pharmaceuticals, Inc. (AGIO) Discusses FDA Approval of AQVESME for Anemia in Alpha and Beta Thalassemia Transcript
Positive
Seeking Alpha
one day ago
Agios Pharmaceuticals upgraded to buy (market perform) after FDA approval of Aqvesme for Alpha- or Beta-Thalassemia, despite boxed warning for liver injury. AGIO's commercial upside from thalassemia is capped, with peak sales estimates around $500M, insufficient alone for profitability; SCD approval remains a major potential catalyst. AGIO maintains a strong cash position of $1.3B versus $101M ...
Positive
The Motley Fool
one day ago
The new indication is relatively rare in the U.S., but pricing is substantial, and the need for the treatment is significant. The positive update turns the company's fortunes around after a disappointing update earlier in the year.
More Agios Pharmaceuticals, Inc. News

Company Profile

Agios Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery and development of novel investigational medicines to treat cancer and rare genetic diseases. It focuses on diseases that are directly caused by changes in genes or chromosomes, often passed from one generation to the next. The company was founded by Lewis Clayton Cantley, Tak W. Mak, Craig B. Thompson and Shin-Shan Michael Su on August 7, 2007 and is headquartered in Cambridge, MA.

Head office United States
CEO Brian Goff
Employees 487
Founded 2007
Website www.agios.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today